Company Name: Paradigm Biopharmaceuticals
Announcement Date: 09/06/2016
Announcement Category: Awards/recognition, Other, Product launch/update
Announcement Content:
A radical treatment for a common sporting injury could put an end to the need for knee replacements. Researchers hope reducing bone bruising in patients with torn cruciate ligaments will stop them developing painful osteoarthritis. Watch the Channel 7 news story here.
Announcement URL: http://paradigmbiopharma.com/investors/media-analyst-reports
About Paradigm Biopharmaceuticals:
Paradigm Biopharmaceuticals (PAR) listed on the ASX in August 2015. We focus on re-purposing pentosan polysulphate sodium (PPS) for new orthopaedic and respiratory applications. We focus on PPS because this FDA-approved drug has a long history of safety and efficacy in treating interstitial cystitis and deep vein thrombosis. Our patents cover new applications in bone marrow edema (BME) and and the allergic inflammatory response in allergic rhinitis (AR), which is commonly known as ‘Hay Fever’.
Go to Company Profile for: Paradigm Biopharmaceuticals
Announcement Contact: [email protected]
